JP2024517738A5 - - Google Patents

Info

Publication number
JP2024517738A5
JP2024517738A5 JP2023566493A JP2023566493A JP2024517738A5 JP 2024517738 A5 JP2024517738 A5 JP 2024517738A5 JP 2023566493 A JP2023566493 A JP 2023566493A JP 2023566493 A JP2023566493 A JP 2023566493A JP 2024517738 A5 JP2024517738 A5 JP 2024517738A5
Authority
JP
Japan
Application number
JP2023566493A
Other languages
Japanese (ja)
Other versions
JP2024517738A (ja
JPWO2022232179A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026396 external-priority patent/WO2022232179A1/en
Publication of JP2024517738A publication Critical patent/JP2024517738A/ja
Publication of JP2024517738A5 publication Critical patent/JP2024517738A5/ja
Publication of JPWO2022232179A5 publication Critical patent/JPWO2022232179A5/ja
Pending legal-status Critical Current

Links

JP2023566493A 2021-04-26 2022-04-26 新規のn,n-ジメチルトリプタミン組成物および方法 Pending JP2024517738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26
US63/179,679 2021-04-26
PCT/US2022/026396 WO2022232179A1 (en) 2021-04-26 2022-04-26 Novel n,n-dimethyltryptamine compositions and methods

Publications (3)

Publication Number Publication Date
JP2024517738A JP2024517738A (ja) 2024-04-23
JP2024517738A5 true JP2024517738A5 (https=) 2025-05-07
JPWO2022232179A5 JPWO2022232179A5 (https=) 2025-05-07

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566493A Pending JP2024517738A (ja) 2021-04-26 2022-04-26 新規のn,n-ジメチルトリプタミン組成物および方法

Country Status (12)

Country Link
US (1) US11602521B2 (https=)
EP (1) EP4329879A4 (https=)
JP (1) JP2024517738A (https=)
KR (1) KR20240000516A (https=)
CN (1) CN117320711A (https=)
AU (1) AU2022267240A1 (https=)
BR (1) BR112023022195A2 (https=)
CA (1) CA3216889A1 (https=)
CL (1) CL2023003191A1 (https=)
IL (1) IL308074A (https=)
MX (1) MX2023012651A (https=)
WO (1) WO2022232179A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
IL308816A (en) * 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス, インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
KR20250005175A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 양극성 장애의 치료를 위한 5-meo-dtm
CA3267555A1 (en) * 2022-10-26 2024-05-02 Atai Therapeutics, Inc. Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids
AU2024242138A1 (en) 2023-03-31 2025-11-13 Cybin Uk Ltd Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
WO2025054397A1 (en) * 2023-09-08 2025-03-13 Atai Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025076151A1 (en) * 2023-10-02 2025-04-10 Atai Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
MD3927338T2 (ro) * 2019-02-22 2025-03-31 Gh Res Ireland Limited Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale
EP4353314A3 (en) 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
JP7617927B2 (ja) * 2019-12-31 2025-01-20 キュア ファーマシューティカル, インコーポレイテッド 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2021259962A1 (en) * 2020-06-22 2021-12-30 University Of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
CN116056705A (zh) * 2020-08-05 2023-05-02 巴塞尔大学医院 用于dmt辅助心理疗法的静脉内dmt施用方法
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement

Similar Documents

Publication Publication Date Title
JP2024517738A5 (https=)
CL2025003148A1 (es) Proceso y aparato para preparar trióxido de azufre a partir de dióxido de azufre
BR102022025291A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BY13170U (https=)
BY13165U (https=)
CN307046546S (https=)
CN307046072S (https=)
CN307045637S (https=)
CN307045278S (https=)
CN307044452S (https=)
CN307044282S (https=)
BY13159U (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
CN307047710S (https=)
BY13174U (https=)
BY13172U (https=)
BY13161U (https=)